Skip to main content

Arbitration of pharmaceutical and life sciences disputes can raise a set of legal and economic concerns different from those found in litigation. What considerations do you need to keep in mind during pharma arbitration—especially in relation to valuation or payment obligations?

On 27 July 2021 at 1 PM EDT, Ellen Oberwetter, Partner at Williams & Connolly LLP, will join Dr. Christine Meyer, Chair of NERA Economic Consulting’s Intellectual Property Practice and Directors Kristopher Boushie and Dr. Chris Stomberg for the webinar discussion “Pay What? Arbitrating Disputes in Pharmaceutical Contracts.”

Our speakers will discuss:

  • Types of disputes in pharma and life sciences that lend themselves to arbitration rather than litigation;
  • Legal considerations in arbitration that differ from those that arise in litigation;
  • Unique valuation issues in pharmaceutical arbitration; and
  • Kinds of economic testimony often seen in pharma arbitration.


NERA Economic Consulting is accredited by the State Bar of California (#19366) as a provider of continuing legal education. The program is being held with the intention that its attendees qualify for 1.0 CLE credit hour in areas of professional practice.